Aier(SZ:300015) Western Securities·2025-11-19 11:18Investment Rating - The report maintains a "Buy" rating for the company [5][3] Core Insights - The company achieved total revenue of 17.484 billion yuan in Q1-Q3 2025, representing a year-on-year growth of 7.25%. However, the net profit attributable to shareholders decreased by 9.76% to 3.115 billion yuan, with a gross margin decline of 1.74 percentage points to 49.27% [1][5] - In Q3 2025, the company reported revenue of 5.977 billion yuan, a year-on-year increase of 3.83%, while the net profit attributable to shareholders fell by 24.12% to 1.064 billion yuan, with a gross margin of 50.65% [1][5] - The company plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, totaling 744 million yuan [1] Financial Performance Summary - For the years 2025 to 2027, the company is projected to achieve revenues of 22.499 billion yuan, 24.878 billion yuan, and 27.490 billion yuan, with year-on-year growth rates of 7.2%, 10.6%, and 10.5% respectively [3] - The net profit attributable to shareholders is expected to be 3.771 billion yuan, 4.249 billion yuan, and 4.892 billion yuan for the same years, reflecting growth rates of 6.0%, 12.7%, and 15.1% respectively [3] - The earnings per share (EPS) are forecasted to be 0.40 yuan, 0.46 yuan, and 0.52 yuan for 2025, 2026, and 2027 respectively [3] Strategic Developments - The company has established 169 overseas ophthalmology centers and clinics, creating a global medical service network. It focuses on retaining local brands and management teams post-acquisition while integrating advanced practices from abroad [2] - The company continues to expand its domestic presence through the "1+8+N" model, enhancing core city hospitals' leadership roles and integrating regional medical resources [2] - Recent acquisitions include three medical institutions for a total of 105 million yuan, with expected combined revenues of 72.13 million yuan and net profits of 13.88 million yuan in 2024 [2]